Alnylam Pharmaceuticals, Inc. (ALNY) by event type

ALNY moves most on analyst upgrades — a median of +0.61% at 30 minutes across 35 measured events. Each row is measured over the last three years and read against the price at its own news timestamp. Back to the ALNY overview →

By event type

How ALNY reacts across 6 measured event types.

EventEventsMedian 30-min% positiveMedian to close
Analyst upgrades
283 of 2,717
35+0.61%63%+0.97%
Analyst downgrades
1,679 of 2,603
26-0.10%46%+0.43%
Coverage initiations
1,659 of 2,283
31-0.20%45%+0.75%
Rating reiterations
1,261 of 3,522
262+0.04%52%+0.42%
Price-target raises
369 of 1,790
78+0.12%56%+0.73%
Price-target cuts
1,054 of 1,527
43-0.10%47%+0.27%

Last 3 years, pulled 2026-09-21. Reaction = percent move vs. the price at the news timestamp. Counts and medians only. The rank under each event type orders every name measured for it by median 30-min reaction, most positive first — so a low rank on a downgrade means this name falls harder than most, not that it moves less. Names with an identical median share a rank; a name the cross-section does not carry shows no rank rather than a guessed one.

That’s how ALNY usually reacts — get an email when it moves on news →
Keep exploring

Every name measured for these event types: Analyst upgrades → · Analyst downgrades → · Coverage initiations → · Rating reiterations → · Price-target raises → · Price-target cuts → · ALNY overview →

Other Healthcare names, measured the same way

TickerEventsMedian 30-min% positive
ENDOCYTE (ECYT)671-0.08%46%
PolarityTE, Inc. (PTE)670-0.62%38%
UroGen Pharma Ltd. - Ordinary Shares (URGN)664+0.13%53%
Brainstorm Cell Therapeutics Inc. (BCLI)6600.00%47%

Same sector, same measurement: percent move vs. the price at the news timestamp, read at 30 minutes. Sample sizes differ, so the medians are comparable but the confidence behind them is not.